Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
HIV infection exerts a negative impact on the course of HCV infection. Co-infected
individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those
infected with HCV alone. Some of the this accelerated fibrosis may be related to longterm
chronic toxicity from protease inhibitor based ART.
Hypothesis: Switching from ritonavir boosted-PI based ART regimen to a Raltegravir-based
regimen will reduce the rate of hepatic fibrosis progression in HIV-HCV co-infected patients
as measured by transient elastography (Fibroscan®) and the AST-to-platelet ratio index
(APRI).
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators:
CIHR Canadian HIV Trials Network Merck Sharp & Dohme Corp.